المؤلفون: Rodriguez, A, Korzeniowska, K, Szarejko, K, Borowski, H, Mysliwiec, M, Brzezinski, M, Czupryniak, L, Berggren, PO, Radziwill, M, Soszynski, P

المصدر: Obesity research & clinical practice. 17(1):86-90

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:152071101Test

المؤلفون: Brzeziński, M, Korzeniowska, K, Szarejko, K, Radziwiłł, M, Myśliwiec, M, Anyszek, T, Czupryniak, L, Berggren, PO, Soszyński, P

المصدر: Pediatric endocrinology, diabetes, and metabolism. 26(1):22-26

مصطلحات موضوعية: Medicin och hälsovetenskap, Hälsovetenskap, Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi, Klinisk medicin, Pediatrik

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:232418419Test

المؤلفون: Rodriguez, A, Korzeniowska, K, Szarejko, K, Borowski, H, Brzezinski, M, Mysliwiec, M, Czupryniak, L, Berggren, PO, Radziwill, M, Soszynski, P

المصدر: Nutrients. 14(7)

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:149236870Test

المؤلفون: Korzeniowska, KA, Brzezinski, M, Szarejko, K, Radziwill, M, Anyszek, T, Czupryniak, L, Soszynski, P, Berggren, PO, Mysliwiec, M

المصدر: Endokrynologia Polska. 70(2):172-178

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:141362759Test

المؤلفون: Mieczkowski M, Mrozikiewicz-Rakowska B, Siwko T, Bujalska-Zadrozny M, de Corde-Skurska A, Wolinska R, Gasinska E, Grzela T, Foltynski P, Kowara M, Mieczkowska Z, Czupryniak L

المصدر: Diabetes, Metabolic Syndrome and Obesity, Vol Volume 14, Pp 1505-1517 (2021)

مصطلحات موضوعية: diabetes mellitus, neuropathy, ulceration, animal model, Specialties of internal medicine, RC581-951

الوصف: Mateusz Mieczkowski,1 Beata Mrozikiewicz-Rakowska,1 Tomasz Siwko,1 Magdalena Bujalska-Zadrozny,2 Anna de Corde-Skurska,2 Renata Wolinska,2 Emilia Gasinska,2 Tomasz Grzela,3 Piotr Foltynski,4 Michal Kowara,5 Zofia Mieczkowska,1 Leszek Czupryniak1 1Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland; 2Department of Pharmacodynamics, Medical University of Warsaw, Warsaw, Poland; 3Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland; 4Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, Warsaw, Poland; 5Department of Cardiology, Medical University of Warsaw, Warsaw, PolandCorrespondence: Beata Mrozikiewicz-RakowskaDepartment of Diabetology and Internal Medicine, Medical University of Warsaw, Poland ul. Banacha 1A, Warsaw, 02-097, PolandTel +48 600 311 399Fax +48225992832Email rakowskab123@gmail.comPurpose: Optimal glycemic control is crucial for proper wound healing in patients with diabetes. However, it is not clear whether other antidiabetic drugs support wound healing in mechanisms different from the normalization of blood glucose control. We assessed the effect of insulin and metformin administration on the wound healing process in rats with streptozotocin-induced diabetes.Methods: The study was conducted on 200 male Wistar rats with streptozotocin-induced diabetes. In the last phase of the study, 45 rats, with the most stable glucose levels in the range of 350– 500 mg/dL, were divided into three groups: group I received human non-protamine insulin subcutaneously (5 IU/kg body mass) once a day, group II received metformin intragastrically (500 mg/kg b.m.), and group III (control) was given saline subcutaneously. After 14 days of antidiabetic treatment, a 2 cm × 2 cm thin layer of skin was cut from each rat’s dorsum and a 4 cm disk with a hole in its center was sewn in to stabilize the skin and standardize the healing process. The wound healing process was followed up for 9 days, with assessment every 3 days. Biopsy samples were subjected to hematoxylin and eosin staining and immunohistochemical assays.Results: Analysis of variance revealed significant influence of treatment type (insulin, control, or metformin) on the relative change in wound surface area. The wound healing process in rats treated with insulin was more effective than in the metformin and control groups. Wound tissue samples taken from the insulin-treated animals presented significantly lower levels of inflammatory infiltration. Immunohistochemical assessment showed the greatest density of centers of proliferation Ki-67 in insulin-treated animals.Conclusion: These results suggest that an insulin-based treatment is more beneficial than metformin, in terms of accelerating the wound healing process in an animal model of streptozocin-induced diabetes.Keywords: diabetes mellitus, neuropathy, ulceration, animal model

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/insulin-but-not-metformin-supports-wound-healing-process-in-rats-with--peer-reviewed-article-DMSOTest; https://doaj.org/toc/1178-7007Test

الوصول الحر: https://doaj.org/article/3275c3f5dabd4acb8c45f6ea5cfea5dbTest

المؤلفون: Rodriguez, A, Korzeniowska, K, Szarejko, K, Borowski, H, Brzeziński, M, Myśliwiec, M, Czupryniak, L, Berggren, P-O, Radziwiłł, M, Soszyński, P

المصدر: 90 ; 86

الوصف: Using data from a large-scale screening program (N = 19634), we aimed to prospectively identify factors predicting uptake (i.e. acceptance of the invitation) and engagement (i.e. participation in at least two sessions) in a multi-component-intensive-behavioral-intervention for obesity-management (MBIOM) intervention targeting adolescents (n = 2862; 12–14 years; BMI ≥90th percentile). Approximately one third of adolescents most in need of weight management declined the initial invitation to enter the MBIOM. Poor diet, sedentary behavior, and parental education predicted willingness to enter and stay in the intervention, however measured body mass index did not matter. Perceived family support, instead of initial motivation, facilitated engagement. Our results provide new insights on the importance of regional socio-geographical factors including trust in local authorities.

العلاقة: Obesity Research & Clinical Practice; http://hdl.handle.net/10044/1/100955Test

الإتاحة: https://doi.org/10.1016/j.orcp.2022.11.002Test
http://hdl.handle.net/10044/1/100955Test

المؤلفون: Janez, A, Muzurovic, E, Stoian, A, Haluzik, M, Guja, C, Czupryniak, L, Duvnjak, L, Lalic, N, Tankova, T, Bogdanski, P, Papanas, N, Silva Nunes, J, Kempler, P, Fras, Z, Rizzo, M

مصطلحات موضوعية: HCC END, Humans, Cardiovascular Diseases* / drug therapy, Cardiovascular Diseases* / epidemiology, Diabetes Mellitus, Type 2* / diagnosis, Type 2* / drug therapy, Type 2* / epidemiology, Glucagon-Like Peptide 1 / metabolism, Glucagon-Like Peptide-1 Receptor / agonists, Hypoglycemic Agents / pharmacology, Hypoglycemic Agents / therapeutic use, Liraglutide / pharmacology, Liraglutide / therapeutic use

الوصف: Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice. ; info:eu-repo/semantics/publishedVersion

العلاقة: Int J Cardiol . 2022 Oct 15:365:8-18.; http://hdl.handle.net/10400.17/4835Test

الإتاحة: https://doi.org/10.1016/j.ijcard.2022.07.017Test
http://hdl.handle.net/10400.17/4835Test

المؤلفون: Janež, A, Guja, C, Mitrakou, A, Lalic, N, Tankova, T, Czupryniak, L, Tabák, AG, Prazny, M, Martinka, E, Smircic-Duvnjak, L

المصدر: Diabetes Therapy , 11 (2) pp. 387-409. (2020)

مصطلحات موضوعية: Continuous subcutaneous insulin infusion, Glycemic control, Insulin analogue, Insulin therapy, Multiple daily injections, Type 1 diabetes mellitus

الوصف: Here, we review insulin management options and strategies in nonpregnant adult patients with type 1 diabetes mellitus (T1DM). Most patients with T1DM should follow a regimen of multiple daily injections of basal/bolus insulin, but those not meeting individual glycemic targets or those with frequent or severe hypoglycemia or pronounced dawn phenomenon should consider continuous subcutaneous insulin infusion. The latter treatment modality could also be an alternative based on patient preferences and availability of reimbursement. Continuous glucose monitoring may improve glycemic control irrespective of treatment regimen. A glycemic target of glycated hemoglobin < 7% (53 mmol/mol) is appropriate for most nonpregnant adults. Basal insulin analogues with a reduced peak profile and an extended duration of action with lower intraindividual variability relative to neutral protamine Hagedorn insulin are preferred. The clinical advantages of basal analogues compared with older basal insulins include reduced injection burden, better efficacy, lower risk of hypoglycemic episodes (especially nocturnal), and reduced weight gain. For prandial glycemic control, any rapid-acting prandial analogue (aspart, glulisine, lispro) is preferred over regular human insulin. Faster-acting insulin aspart is a relatively new option with the advantage of better postprandial glucose coverage. Frequent blood glucose measurements along with patient education on insulin dosing based on carbohydrate counting, premeal blood glucose, and anticipated physical activity is paramount, as is education on the management of blood glucose under different circumstances. Plain Language Summary: Plain language summary is available for this article.

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10095357/1/117_JanezADiabetesTher2020.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10095357Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10095357/1/117_JanezADiabetesTher2020.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10095357Test/

المؤلفون: Kalra, S, Czupryniak, L, Kilov, G, Lamptey, R, Kumar, A, Unnikrishnan, AG, Boudiba, A, Abid, M, Akanov, ZA, Latheef, A, Araz, M, Audehm, R, Bahendeka, S, Balde, N, Chaudhary, S, Deerochanawong, C, Fasanmade, O, Iraqi, H, Latt, TS, Mbanya, JC, Rodriguez-Saldana, J, Hyun, KS, Latif, ZA, Lushchyk, M, Megallaa, M, Naseri, MW, Nguyen, QB, Ramaiya, K, Randeree, H, Raza, SA, Shaikh, K, Shrestha, D, Sobngwi, E, Somasundaram, N, Sukor, N, Tan, R

الوصف: Premixed insulins are an important tool for glycemic control in persons with diabetes. Equally important in diabetes care is the selection of the most appropriate insulin regimen for a particular individual at a specific time. Currently, the choice of insulin regimens for initiation or intensification of therapy is a subjective decision. In this article, we share insights, which will help in rational and objective selection of premixed formulations for initiation and intensification of insulin therapy. The glycemic status and its variations in a person help to identify the most appropriate insulin regimen and formulation for him or her. The evolution of objective glucometric indices has enabled better glycemic monitoring of individuals with diabetes. Management of diabetes has evolved from a 'glucocentric' approach to a 'patient-centered' approach; patient characteristics, needs, and preferences should be evaluated when considering premixed insulin for treatment of diabetes.Funding: Novo Nordisk, India.

العلاقة: pii: 10.1007/s13300-018-0521-2; Kalra, S., Czupryniak, L., Kilov, G., Lamptey, R., Kumar, A., Unnikrishnan, A. G., Boudiba, A., Abid, M., Akanov, Z. A., Latheef, A., Araz, M., Audehm, R., Bahendeka, S., Balde, N., Chaudhary, S., Deerochanawong, C., Fasanmade, O., Iraqi, H., Latt, T. S. ,. Tan, R. (2018). Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. DIABETES THERAPY, 9 (6), pp.2185-2199. https://doi.org/10.1007/s13300-018-0521-2Test.; http://hdl.handle.net/11343/269832Test

الإتاحة: https://doi.org/10.1007/s13300-018-0521-2Test
http://hdl.handle.net/11343/269832Test

المؤلفون: Giorgino F., Bhana S., Czupryniak L., Dagdelen S., Galstyan G. R., Janez A., Lalic N., Nouri N., Rahelic D., Stoian A. P., Raz I.

المساهمون: Giorgino, F., Bhana, S., Czupryniak, L., Dagdelen, S., Galstyan, G. R., Janez, A., Lalic, N., Nouri, N., Rahelic, D., Stoian, A. P., Raz, I.

مصطلحات موضوعية: Consensu, COVID-19, Diabete, Management, Obesity, Pandemic

الوصف: The COVID-19 pandemic has had a major effect on healthcare during 2020. Current evidence suggests that, while individuals with diabetes and obesity are no more prone to SARS-CoV-2 infection than those without, the risk of hospitalisation if someone has diabetes or obesity and then contracts COVID-19 is three times higher – and 4.5 times higher if they have diabetes and obesity. We assembled a panel of experts from South and East Europe, the Middle East, and Africa to discuss the challenges to management of diabetes and obesity during and post the COVID-19 pandemic. The experience and learnings of this panel cover a heterogeneous patient population, wide range of clinical settings, healthcare organisations, disease management strategies, and social factors. We discuss the importance of timely and effective disease management via telemedicine, providing reassurance and guidance for patients unable or unwilling to visit healthcare settings at this time. We address the use of novel therapies and their role in managing diabetes and obesity during the pandemic, as well as the importance of controlling hypoglycaemia and preventing cardiovascular complications, particularly in vulnerable people. Finally, we consider post-COVID-19 management of diabetes and obesity, and how these learnings and experiences should impact upon future clinical guidelines.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33310175; info:eu-repo/semantics/altIdentifier/wos/WOS:000632553000002; volume:172; firstpage:108617; journal:DIABETES RESEARCH AND CLINICAL PRACTICE; http://hdl.handle.net/11586/353509Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85099183945

الإتاحة: https://doi.org/10.1016/j.diabres.2020.108617Test
http://hdl.handle.net/11586/353509Test